IMPEL NEUROPHARMA INC (IMPL): Price and Financial Metrics
IMPL Price/Volume Stats
| Current price | $0.04 | 52-week high | $4.20 |
| Prev. close | $0.06 | 52-week low | $0.02 |
| Day low | $0.02 | Volume | 720,000 |
| Day high | $0.05 | Avg. volume | 682,655 |
| 50-day MA | $0.34 | Dividend yield | N/A |
| 200-day MA | $0.97 | Market Cap | 956.00K |
IMPL Stock Price Chart Interactive Chart >
IMPEL NEUROPHARMA INC (IMPL) Company Bio
Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
IMPL Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...